Polypharmacy with antidepressants in children and adolescents

International Journal of Neuropsychopharmacology

Volumn 17, Issue 7, 2014, Pages 1063-1082

  Díaz Caneja, Covadonga M ^a   Espliego, Ana ^a   Parellada, Mara ^a   Arango, Celso ^a   Moreno, Carmen ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Adolescent; antidepressant; child; polypharmacy; SSRI

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATOMOXETINE; BUSPIRONE; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; LITHIUM; NEUROLEPTIC AGENT; PAROXETINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; VALPROATE SEMISODIUM; VENLAFAXINE;

ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; CHILD HEALTH CARE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR DEPRESSION; MEDLINE; MOOD DISORDER; MORBIDITY; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT RESISTANT DEPRESSION; ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DEPRESSIVE DISORDER; OBSESSIVE-COMPULSIVE DISORDER;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DEPRESSIVE DISORDER; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; POLYPHARMACY; PSYCHOTROPIC DRUGS;

EID: 84901419612     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145712001265     Document Type: Review

References (153)

1. Abikoff H, McGough J, Vitiello B, McCracken J, et al. (2005) Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry 44:418-427.
2. Aldurra G, Crayton JW (2001) Improvement of hallucinogen persisting perception disorder by treatment with a combination of fluoxetine and olanzapine: case report. J Clin Psychopharmacol 21:343-344.
3. Alessi N, Bos T (1991) Buspirone augmentation of fluoxetine in a depressed child with obsessive-compulsive disorder. Am J Psychiatry 148:1605-1606.
4. American Academy of Children and Adolescent Psychiatry (1998) Practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 37:27S-45S.
5. American Academy of Children and Adolescent Psychiatry (2009) Practice parameter on the use of psychotropic medication in children and adolescents. J Am Acad Child Adolesc Psychiatry 48:961-973.
6. Anagnostou E, Esposito K, Soorya L, Chaplin W, et al. (2006) Divalproex vs placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder. J Clin Psychopharmacol 26:444-446.
7. Andersen SW, Clemow DB, Corya SA (2005). Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. J Clin Psychiatry 66:1468-1476.
8. APA (2000). Diagnostic criteria from DSM-IV-TR. Washington, DC: American Psychiatric Association.
9. APA(2006). American Psychiatric Association practice guidelines for the treatment of psychiatric disorders : Compendium. Washington, DC: American Psychiatric Association.
10. Baird R (2003). Methylphenidate and the cytochrome P450 system. Can J Psychiatry 48:425-426.
11. Belle DJ, Ernest CS, Sauer JM, Smith BP, et al. (2002). Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 42:1219-1227.
12. Bhatara VS, Feil M, Hoagwood K, Vitiello B, et al. (2004). National trends in concomitant psychotropic medication with stimulants in pediatric visits : practice vs knowledge. J Attent Disord 7 :217-226.
13. Biederman J, Mick E, Spencer TJ, Wilens TE, et al. (2000). Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young. J Child Adolesc Psychopharmacol 10:185-192.
14. Birmaher B, Brent D, Bernet W, Bukstein O, et al. (2007). Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 46:1503-1526.
15. Blader JC, Carlson GA (2007). Increased rates of bipolar disorder diagnoses among U.S. child, adolescent, and adult inpatients, 1996-2004. Biol Psychiatry 62:107-114.
16. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, et al. (2006). A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11:622-632.
17. Bridge JA, Iyengar S, Salary CB, Barbe RP, et al. (2007). Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a metaanalysis of randomized controlled trials. J Am Med Assoc 297:1683-1696.
18. Budman CL, Sherling M, Bruun RD (1995). Combined pharmacotherapy risk. J Am Acad Child Adolesc Psychiatry 34:263-264.
19. Burke MS, Josephson A, Lightsey A (1995). Combined methylphenidate and imipramine complication. J Am Acad Child Adolesc Psychiatry 34:403-404.
20. Bussing R, Levin GM (1993). Methamphetamine and fluoxetine treatment of a child with attention-deficit hyperactivity disorder and obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 3:53-58.
21. Caldwell PH, Murphy SB, Butow PN, Craig JC (2004). Clinical trials in children. Lancet 364:803-811.
22. Cheung AH, Emslie GJ, Mayes TL (2005). Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry 46:735-754.
23. Comer JS, Olfson M, Mojtabai R (2010). National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. J Am Acad Child Adolesc Psychiatry 49:1001-1010.
24. Connor DF, Ozbayrak KR, Kusiak KA, Caponi AB, et al. (1997). Combined pharmacotherapy in children and adolescents in a residential treatment center. J Am Acad Child Adolesc Psychiatry 36:248-254.
25. Correll CU, Carlson HE (2006). Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:771-791.
26. Coskun M, Zoroglu S (2008). Tactile and visual hallucinations in a child with methylphenidate and fluoxetine combination. J Clin Psychopharmacol 28:723-725.
27. Costello EJ, Mustillo S, Erkanli A, Keeler G, et al. (2003). Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry 60:837-844.
28. Crossley NA, Bauer M (2007). Acceleration and augmentation of antidepressants with lithium for depressive disorders : two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 68:935-940.
29. Cruz-Flores S, Hayat GR, Mirza W (1995). Valproic toxicity with fluoxetine therapy. Mo Med 92:296-297.
30. Curtis AR, Richards RW (2007). The treatment of psychogenic excoriation and obsessive compulsive disorder using aripiprazole and fluoxetine. Ann Clin Psychiatry 19:199-200.
31. Dadic-Hero E, Ruzic K, Pernar M, Kabalin M, et al. (2009). Olanzapine treatment in anorexia nervosa: case report. Psychiat Danubina 21:122-125.
32. Daniel DG, Smith K, Hyde T, Egan M (1996). Neurolepticinduced tardive dyskinesia. Am J Psychiatry 153:734.
33. Daviss WB, Bentivoglio P, Racusin R, Brown KM, et al. (2001). Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry 40:307-314.
34. Dean AJ, McDermott BM, Marshall RT (2006). Psychotropic medication utilization in a child and adolescent mental health service. J Child Adolesc Psychopharmacol 16:273-285.
35. DeBattista C, Hawkins J (2009). Utility of atypical antipsychotics in the treatment of resistant unipolar depression. CNS Drugs 23:369-377.
36. de Wit M, Snoek FJ (2011). Depressive symptoms and unmet psychological needs of Dutch youth with type 1 diabetes : results of a web-survey. Pediatr Diabetes 12:172-176.
37. dosReis S, Zito JM, Safer DJ, Gardner JF, et al. (2005). Multiple psychotropic medication use for youths: a two-state comparison. J Child Adolesc Psychopharmacol 15, 68-77.
38. Dubicka B, Hadley S, Roberts C (2006). Suicidal behaviour in youths with depression treated with new-generation antidepressants : meta-analysis. Br J Psychiatry 189:393-398.
39. Duffy FF, Narrow WE, Rae DS, West JC, et al. (2005). Concomitant pharmacotherapy among youths treated in routine psychiatric practice. J Child Adolesc Psychopharmacol 15:12-25.
40. Duggal HS, Pathak PC, Coleman CC (2003). Treating selective serotonin reuptake inhibitor-induced behavioral activation with valproate. J Child Adolesc Psychopharmacol 13:113-114.
41. Ercan ES, Copkunol H, Cykoethlu S, Varan A (2003). Olanzapine treatment of an adolescent girl with anorexia nervosa. Hum Psychopharmacol 18:401-403.
42. Esbjorn BH, Hoeyer M, Dyrborg J, Leth I, et al. (2010). Prevalence and co-morbidity among anxiety disorders in a national cohort of psychiatrically referred children and adolescents. J Anxiety Disord 24:866-872.
43. Essau CA (2008). Comorbidity of depressive disorders among adolescents in community and clinical settings. Psychiatry Res 158:35-42.
44. Faber A, de Jong-van den Berg LT, van den Berg PB, Tobi H (2005). Psychotropic co-medication among stimulant-treated children in The Netherlands. J Child Adolesc Psychopharmacol 15:38-43.
45. Faraone SV, Biederman J, Morley CP, Spencer TJ (2008). Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 47:994-1009.
46. Feeney DJ, Klykylo WM (1997). Medication-induced seizures. J Am Acad Child Adolesc Psychiatry 36:1018-1019.
47. Fegert JM, Kolch M, Zito JM, Glaeske G, et al. (2006). Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol 16:197-206.
48. Figueroa Y, Rosenberg DR, Birmaher B, Keshavan MS (1998). Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. J Child Adolesc Psychopharmacol 8:61-67.
49. Findling RL (1996). Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults : a case series. J Child Adolesc Psychopharmacol 6 :165-175.
50. Findling RL, Lingler J, Rowles BM, McNamara NK, et al. (2008). A pilot pharmacotherapy trial for depressed youths at high genetic risk for bipolarity. J Child Adolesc Psychopharmacol 18:615-621.
51. Fitzgerald KD, Stewart CM, Tawile V, Rosenberg DR (1999). Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharmacol 9 :115-123.
52. Fontanella CA, Bridge JA, Campo JV (2009). Psychotropic medication changes, polypharmacy, and the risk of early readmission in suicidal adolescent inpatients. Ann Pharmacother 43:1939-1947.
53. Fraguas D, Correll CU, Merchan-Naranjo J, Rapado-Castro M, et al. (2011). Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders : comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 21:621-645.
54. Fraguas D, Merchan-Naranjo J, Arango C (2010). Differential characteristics of the efficacy and tolerability of secondgeneration antipsychotics in the treatment of psychotic disorders in children and adolescents. Rev Psiquiat Salud Ment 3:152-167.
55. Gammon GD, Brown TE (1993). Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol 3:1-10.
56. Geller B, Tillman R, Bolhofner K, Zimerman B (2010). Pharmacological and non-drug treatment of child bipolar I disorder during prospective eight-year follow-up. Bipolar Disord 12:164-171.
57. Geller D, Donnelly C, Lopez F, Rubin R, et al. (2007). Atomoxetine treatment for pediatric patients with attentiondeficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 46:1119-1127.
58. Geller DA, Biederman J, Reed ED, Spencer T, et al. (1995). Similarities in response to fluoxetine in the treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 34:36-44.
59. George AK, Kunwar AR, Awasthi A (2005). Acute myocardial infarction in a young male on methylphenidate, bupropion, and erythromycin. J Child Adolesc Psychopharmacol 15:693-695.
60. Ghaziuddin N, Iqbal A, Khetarpal S (2001). Myoclonus during prolonged treatment with sertraline in an adolescent patient. J Child Adolesc Psychopharmacol 11:199-202.
61. Gibbons RD, Hur K, Bhaumik DK, Mann JJ (2006). The relationship between antidepressant prescription rates and rate of early adolescent suicide. Am J Psychiatry 163:1898-1904.
62. Good CR (2006). Adjunctive quetiapine targets selfharm behaviors in adolescent females with major depressive disorder. J Child Adolesc Psychopharmacol 16:235-236.
63. Graham J, Coghill D (2008). Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder : epidemiology, prevention and management. CNS Drugs 22:213-237.
64. Hammad TA, Laughren TP, Racoosin JA (2006). Suicide rates in short-term randomized controlled trials of newer antidepressants. J Clin Psychopharmacol 26:203-207.
65. Hawkridge S, Stein DJ, Bouwer C (1996). Combined pharmacotherapy for TS and OCD. J Am Acad Child Adolesc Psychiatry 35:703-704.
66. Hetrick S, Merry S, McKenzie J, Sindahl P, et al. (2007). Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev 18:CD004851.
67. Hughes CW, Emslie GJ, Crismon ML, Posner K, et al. (2007). Texas children's medication algorithm project : update from texas consensus conference panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry 46:667-686.
68. Hunkeler EM, Fireman B, Lee J, Diamond R, et al. (2005). Trends in use of antidepressants, lithium, and anticonvulsants in Kaiser Permanente-insured youths, 1994-2003. J Child Adolesc Psychopharmacol 15:26-37.
69. Ickowicz A (2002). Bupropion-methylphenidate combination and grand mal seizures. Can J Psychiatry 47:790-791.
70. Jerrell JM, McIntyre RS (2009). Cardiovascular and neurological adverse events associated with antidepressant treatment in children and adolescents. J Child Neurol 29:297-304.
71. Jerrell JM, McIntyre RS (2010). Metabolic, digestive, and reproductive adverse events associated with antimanic treatment in children and adolescents: a retrospective cohort study. Prim Care Companion. J Clin Psychiatry 12. Published online. doi :10.4088/PCC.09m00891ora.
72. Kastelic EA, Labellarte MJ, Riddle MA (2000). Selective serotonin reuptake inhibitors for children and adolescents. Curr Psychiatry Rep 2:117-123.
73. Kendall PC, Compton SN, Walkup JT, Birmaher B, et al. (2010). Clinical characteristics of anxiety disordered youth. J Anxiety Disord 24:360-365.
74. Kennard B, Silva S, Vitiello B, Curry J, et al. (2006). Remission and residual symptoms after short-term treatment in the treatment of adolescents with depression study (TADS). J Am Acad Child and Adolesc Psychiatry 45:1404-1411.
75. Koelch M, Prestel A, Singer H, Keller F, et al. (2009). Psychotropic medication in children and adolescents in Germany: prevalence, indications, and psychopathological patterns. J Child Adolesc Psychopharmacol 19:756-770.
76. Kowatch RA, Fristad M, Birmaher B, Wagner KD, et al. (2005). Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 44:213-235.
77. Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, et al. (2005). Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry 44:915-924.
78. Kurtz BP, Abrams AN (2010). Psychiatric aspects of pediatric cancer. Child Adolesc Psychiatric Clin N Am 19:401-421.
79. Larson K, Russ SA, Kahn RS, Halfon N (2011). Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics 127:462-470.
80. Lee E, Teschemaker AR, Johann-Liang R, Bazemore G, et al. (2012). Off-label prescribing patterns of antidepressants in children and adolescents. Pharmacoepidemiol Drug Saf 21:137-144.
81. Libby AM, Orton HD, Valuck RJ (2009). Persisting decline in depression treatment after FDA warnings. Arch Gen Psychiatry 66:633-639.
82. Lopez-Larson M, Frazier JA (2006). Empirical evidence for the use of lithium and anticonvulsants in children with psychiatric disorders. Harv Rev Psychiatry 14:285-304.
83. Ma J, Lee KV, Stafford RS (2005). Depression treatment during outpatient visits by U.S. children and adolescents. J Adolesc Health 37:434-442.
84. McIntyre RS, Jerrell JM (2009). Polypharmacy in children and adolescents treated for major depressive disorder : a claims database study. J Clin Psychiatry 70:240-246.
85. Mahapatra S, Belgrad JL, Adeoye MA (2011). Psychotropic drugrelated eosinophilia with systemic symptoms after acute caffeine ingestion. Pediatrics 127:e235-e238.
86. Mancini J, Thirion X, Masut A, Saillard C, et al. (2006). Anxiolytics, hypnotics, and antidepressants dispensed to adolescents in a French region in 2002. Pharmacoepidemiol Drug Saf 15:494-503.
87. Martin A (2003). Pediatric psychopharmacology: principles and practice. Oxford, New York: Oxford University Press.
88. Martin A, Van Hoof T, Stubbe D, Sherwin T, et al. (2003). Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care. Psychiatr Serv 54:72-77.
89. Masi G, Millepiedi S, Perugi G, Pfanner C, et al. (2009). Pharmacotherapy in paediatric obsessive-compulsive disorder : a naturalistic, retrospective study. CNS Drugs 23:241-252.
90. Masi G, Perugi G, Millepiedi S, Toni C, et al. (2007). Bipolar comorbidity in pediatric obsessive-compulsive disorder : clinical and treatment implications. J Child Adolesc Psychopharmacol 17:475-486.
91. Masi G, Pfanner C, Millepiedi S, Berloffa S (2010). Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. J Clin Psychopharmacol 30:688-693.
92. Merikangas KR, He JP, Burstein M, Swanson SA, et al. (2010). Lifetime prevalence of mental disorders in U.S. adolescents : results from the national comorbidity survey replication-adolescent supplement (NCS-A). J Am Acad Child Adolesc Psychiatry 49:980-989.
93. Moreno C, Laje G, Blanco C, Jiang H, et al. (2007). National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry 64:1032-1039.
94. Moreno C, Merchan-Naranjo J, Alvarez M, Baeza I, et al. (2010). Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord 12:172-184.
95. Moreno C, Roche AM, Greenhill LL (2006). Pharmacotherapy of child and adolescent depression. Child Adolesc Psychiatric Clin N Am 15:977-998.
96. Nagar S, Sherer JT, Chen H, Aparasu RR (2010). Extent of functional impairment in children and adolescents with depression. Curr Med Res Opin 26:2057-2064.
97. Nemeroff CB, Kalali A, Keller MB, Charney DS, et al. (2007). Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry 64:466-472.
98. National Institute for Health and Clinical Excellence (2005a). Depression in children and young people: identification and management in primary, community and secondary care (CG28). London: NICE.
99. National Institute for Health and Clinical Excellence (2005b). Obsessive compulsive disorder : core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder (CG-31). London: NICE.
100. Olfson M, Shaffer D, Marcus SC, Greenberg T (2003a). Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 60:978-982.
101. Olfson M, Gameroff MJ, Marcus SC, Jensen PS (2003b). National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry 160:1071-1077.
102. Olfson M, Marcus SC, Weissman MM, Jensen PS (2002). National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 41:514-521.
103. Oner O, Oner P (2008). Psychopharmacology of pediatric obsessive-compulsive disorder : three case reports. J Psychopharmacol 22:809-811.
104. Owley T, Owley S, Leventhal B, Cook Jr. EH (2002). Case series : Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder. J Child Adolesc Psychopharmacol 12:165-171.
105. Ozcan O, Selimoglu MA (2009). Self-injury behavior in an adolescent with Wilson's disease. Eur Child Adolesc Psychiatry 18:761-762.
106. Padla D (2001). Quetiapine resolves psychotic depression in an adolescent boy. J Child Adolesc Psychopharmacol 11:207-208.
107. Park YM, Jung YK (2010). Manic switch and serotonin syndrome induced by augmentation of paroxetine with methylphenidate in a patient with major depression. Prog Neuropsychopharmacol Biol Psychiatry 34:719-720.
108. Pathak S, Danielyan A, Kowatch RA (2004). Successful treatment of trichotillomania with olanzapine augmentation in an adolescent. J Child Adolesc Psychopharmacol 14:153-154.
109. Pathak S, Johns ES, Kowatch RA (2005). Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder : a case series. J Child Adolesc Psychopharmacol 15:696-702.
110. Pediatric OCD Treatment Study Team (2004). Cognitivebehavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder : the pediatric OCD treatment study (POTS) randomized controlled trial. J Am Acad Med 292:1969-1976.
111. Pliszka SR, Crismon ML, Hughes CW, Corners CK, et al. (2006). The Texas children's medication algorithm project : revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:642-657.
112. Puig-Antich J, Lukens E, Davies M, Goetz D, et al. (1985). Psychosocial functioning in prepubertal major depressive disorders. I. Interpersonal relationships during the depressive episode. Arch Gen Psychiatry 42:500-507.
113. Raghavan R, McMillen JC (2008). Use of multiple psychotropic medications among adolescents aging out of foster care. Psychiatr Serv 59:1052-1055.
114. Reed E, Vance A, Luk E, Nunn K (2004). Single and combined psychotropic medication use in a child and adolescent mental health service. Aust N Z J Psychiatry 38:204-211.
115. Rittmannsberger H (2002). The use of drug monotherapy in psychiatric inpatient treatment. Prog Neuropsychopharmacol Biol Psychiatry 26:547-551.
116. Robison LM, Skaer TL, Sclar DA, Galin RS (2002). Is attention deficit hyperactivity disorder increasing among girls in the US? Trends in diagnosis and the prescribing of stimulants. CNS Drugs 16:129-137.
117. Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, et al. (2011). Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 168:689-701.
118. Rushton JL, Whitmire JT (2001). Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends : 1992 to 1998. Arch Pediatr Adolesc Med 155:560-565.
119. Russell PS, George C, Mammen P (2006). Predictive factors for polypharmacy among child and adolescent psychiatry inpatients. Clin Pract Epidemiol Ment Health 2 :25.
120. Ryan ND, Meyer V, Dachille S, Mazzie D, et al. (1988). Lithium antidepressant augmentation in TCA-refractory depression in adolescents. J Am Acad Child Adolesc Psychiatry 27:371-376.
121. Safer DJ, Zito JM (2006). Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children vs adolescents. J Child Adolesc Psychopharmacol 16:159-169.
122. Safer DJ, Zito JM, DosReis S (2003). Concomitant psychotropic medication for youths. Am J Psychiatry 160:438-449.
123. Sallee FR, DeVane CL, Ferrell RE (2000). Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol 10:27-34.
124. Saunders (2007) Dorland's illustrated medical dictionary, 31st edn. Philadelphia: Saunders.
125. Schertz M, Steinberg T (2008). Seizures induced by the combination treatment of methylphenidate and sertraline. J Child Adolesc Psychopharmacol 18:301-303.
126. Schirm E, Tobi H, Zito JM, de Jong-van den Berg LT (2001). Psychotropic medication in children : a study from the Netherlands. Pediatrics 108:E25.
127. Settle EC (1998). Antidepressant drugs: disturbing and potentially dangerous adverse effects. J Clin Psychiatry 59:25-30.
128. Simeon JG, Thatte S, Wiggins D (1990). Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. Psychopharmacol Bull 26:285-290.
129. Skaer TL, Sclar DA, Robison LM (2009). Trends in prescriptions for antidepressant pharmacotherapy among US children and adolescents diagnosed with depression, 1990 through 2001: an assessment of accordance with treatment recommendations from the American academy of child and adolescent psychiatry. Clin Ther 31:1478-1487.
130. Smathers SA, Wilson JG, Nigro MA (2003). Topiramate effectiveness in Prader-Willi syndrome. Pediatr Neurol 28:130-133.
131. Sourander A (2004). Combined psychopharmacological treatment among child and adolescent inpatients in Finland. Eur Child Adolesc Psychiatry 13:179-184.
132. Srivastava RK, Sharma S, Tiwari N, Saluja B (2005). Olanzapine augmentation of fluoxetine in trichotillomania : two cases. Aust N Z J Psychiatry 39:112-113.
133. Staller JA, Wade MJ, Baker M (2005). Current prescribing patterns in outpatient child and adolescent psychiatric practice in central New York. J Child Adolesc Psychopharmacol 15:57-61.
134. Storch EA, Merlo LJ, Larson MJ, Marien WE, et al. (2008). Clinical features associated with treatment-resistant pediatric obsessive-compulsive disorder. Compr Psychiatry 49:35-42.
135. Strober M, Freeman R, Rigali J, Schmidt S, et al. (1992). The pharmacotherapy of depressive illness in adolescence : II. Effects of lithium augmentation in nonresponders to imipramine. J Am Acad Child Adolesc Psychiatry 31:16-20.
136. Thomsen PH (2004). Risperidone augmentation in the treatment of severe adolescent OCD in SSRI-refractory cases : a caseseries. Ann Clin Psychiatry 16:201-207.
137. Thomsen PH, Mikkelsen HU (1999). The addition of buspirone to SSRI in the treatment of adolescent obsessive-compulsive disorder. A study of six cases. Eur Child Adolesc Psychiatry 8 :143-148.
138. Took KJ, Buck BJ (1996). Enuresis with combined risperidone and SSRI use. J Am Acad Child Adolesc Psychiatry 35:840-841.
139. Usala T, Clavenna A, Zuddas A, Bonati M (2008). Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. Eur Neuropsychopharmacol 18:62-73.
140. Vieta E, Locklear J, Gunther O, Ekman M, et al. (2010). Treatment options for bipolar depression: a systematic review of randomized, controlled trials. J Clin Psychopharmacol 30:579-590.
141. Vitiello B (2008). An international perspective on pediatric psychopharmacology. Int Rev Psychiatry 20:121-126.
142. Wagner KD, Ambrosini P, Rynn M, Wohlberg C, et al. (2003). Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder : two randomized controlled trials. J Am Med Assoc 290:1033-1041.
143. Wagner KD, Robb AS, Findling RL, Jin J, et al. (2004). A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 161:1079-1083.
144. Walter G, Lyndon B, Kubb R (1998). Lithium augmentation of venlafaxine in adolescent major depression. Aust N Z J Psychiatry 32:457-459.
145. Wehr AM, Namerow LB (2001). Citalopram for OCD and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 40:740-741.
146. Weintrob N, Cohen D, Klipper-Aurbach Y, Zadik Z, et al. (2002). Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 156:696-701.
147. WHO (1992). The ICD-10 classification of mental and behavioural disorders : clinical descriptions and diagnostic guidelines. Geneva: World Health Association.
148. Wijkstra J, Lijmer J, Balk FJ, Geddes JR, et al. (2006). Pharmacological treatment for unipolar psychotic depression: systematic review and meta-analysis. Br J Psychiatry 188:410-415.
149. Wilens TE, Biederman J, Kwon A, Chase R, et al. (2004). A systematic chart review of the nature of psychiatric adverse events in children and adolescents treated with selective serotonin reuptake inhibitors. J Child Adolesc Psychopharmacol 13:143-152.
150. Zito JM, Safer DJ, de Jong-van den Berg LT, Janhsen K, et al. (2008). A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health 2 :26.
151. Zito JM, Safer DJ, DosReis S, Gardner JF, et al. (2002). Rising prevalence of antidepressants among US youths. Pediatrics 109:721-727.
152. Zito JM, Tobi H, de Jong-van den Berg LT, Fegert JM, et al. (2006). Antidepressant prevalence for youths: a multinational comparison. Pharmacoepidemiol Drug Saf 15:793-798.
153. Zonfrillo MR, Penn JV, Leonard HL (2005). Pediatric psychotropic polypharmacy. Psychiatry (Edgmont) 2 :14-19.